Table 1 Patient information and dosimetric parameters
Characters | Histology/stage | Patients (n) | Median | Percentage/range |
|---|---|---|---|---|
Age | 56 years | 20–78 years | ||
Histology | Serous | 85 | 56.7% | |
Endometrioid | 41 | 27.3% | ||
Mucinous | 9 | 6.0% | ||
Clear cell | 6 | 4.0% | ||
Mixed type | 9 | 6.0% | ||
FIGO stage | I–II | 28 | 18.7% | |
III–IV | 122 | 81.3% | ||
Histological grade | G1 | 38 | 25.3% | |
G2 | 67 | 44.7% | ||
G3 | 45 | 30.0% | ||
Tumor residual size | 0 cm | 42 | 28.0% | |
≤ 1 cm | 71 | 47.3% | ||
> 1 cm | 37 | 24.7% | ||
Tumor size | ≤ 10 cm | 67 | 44.7% | |
> 10 cm | 83 | 55.3% | ||
Platinum-based | Cisplatin-based | 31 | 20.7% | |
Carboplatin-based | 119 | 79.3% | ||
Follow-up time | 150 | 36.5 months | 2–86 months |